Seasonal H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups.
Immunogen
Hemagglutinin antibody was raised against a synthetic peptide from the Hemagglutinin protein.The peptide sequence is unique from the peptide sequence for product SAB3501244, and SAB3501246. This antibody is a cognate pair with product number SAB3501249. The immunogen is located within amino acids 150 - 200 of Seasonal H1N1 Hemagglutinin.
Application
Hemagglutinin antibody can be used for the detection of the Hemagglutinin protein from the H1N1 strain of common influenza A in ELISA. It will detect 2 ng of free peptide at 1 μg/mL.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
